|
AU3433902A
|
|
Therapies for acute renal failure
|
|
AU9719101A
|
|
Modulators of morphogen expression and methods of identifying the same
|
|
AU7142000A
|
|
Morphogen treatment for chronic renal failure
|
|
AU5349700A
|
|
Morphogen analogs and methods for producing them
|
|
CA2323078A1
|
|
Compositions for modulating cell differentiation comprising a lipid and a morphogen
|
|
AU2330999A
|
|
Methods and compositions for enhancing cognitive function using morphogenic proteins
|
|
CA2314821A1
|
|
Methods for maintaining or restoring tissue-appropriate phenotype of soft tissue cells
|
|
CA2314423A1
|
|
Maintenance of smooth muscle integrity by morphogenic proteins
|
|
AU1122099A
|
|
Enhancement of morphogen activity
|
|
WO9854344A2
|
|
Modulators of morphogen expression and methods of identifying the same
|
|
AU7489398A
|
|
Compositions for morphogen-induced osteogenesis
|
|
CA2289123A1
|
|
Therapies for acute renal failure
|
|
WO9834655A1
|
|
Matrix-free osteogenic devices, implants and methods of use thereof
|
|
WO9827995A1
|
|
Treatment of mammalian myocardium with morphogen locally, or with morphogenically-treated myogenic precursor cells
|
|
AU5244998A
|
|
Morphogen-induced regeneration of sense perceptory tissues
|
|
AU3604097A
|
|
Morphogenic protein screening method II
|
|
AU2942397A
|
|
Morphogen treatment of gastrointestinal ulcers
|
|
AU2582397A
|
|
Methods for enhancing functional recovery following central nervous system ischemia or trauma
|
|
AU2244997A
|
|
Morphogen analogs and methods for producing them
|
|
US6090544A
|
|
Methods and compositions for identifying morphogen analogs
|
